FreeTCCL Archive Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial October 30, 2014Vol.37 No.10
FreeTCCL Archive Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says October 01, 2014Vol.37 No.09
FreeTCCL Archive Cediranib/Olaparib Combination Nearly Doubles PFS in Phase II October 01, 2014Vol.37 No.09
FreeTCCL Archive Phase III Xilonix Study Halted Following Unscheduled Analysis October 01, 2014Vol.37 No.09
FreeTCCL Archive Phase III Trial: Panobinostat Increases PFS by Four Months October 01, 2014Vol.37 No.09
FreeTCCL Archive Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials October 01, 2014Vol.37 No.09
FreeTCCL Archive Pancreatic Neuroendocrine Tumors Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial October 01, 2014Vol.37 No.09
